Cognition Therapeutics provides pipeline update; SHINE interim shows 3-point ADAS-Cog benefit

COGNITION THERAPEUTICS INC

Cash and equivalents $37.2M as of June 30, 2023; expected runway through Q3 2024.
Total grant funding ~$171M; $81.8M remaining as of June 30, 2023.
SHINE Phase 2 interim (n=24) showed 3-point ADAS-Cog-11 difference at Day 185 vs placebo.
Topline data for SHINE (mild-moderate AD) and SHIMMER (DLB) expected mid-2024.
Phase 2 START (early AD) enrolling; MAGNIFY (dry AMD) in development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.